NEW DELHI : An expert committee of the Central Drugs Standard Control Organisation (CDSCO) will meet today to review applications of Pfizer, Serum Institute of India and Bharat Biotech seeking emergency use authorisation for their C-19 vaccine candidates, official sources said.
The decision was taken late on Monday evening after the Hyderabad-based Bharat Biotech became the third pharmaceutical firm to apply to the Drugs Controller General of India (DCGI) for emergency use authorisation for its indigenously developed C-19 vaccine Covaxin.
The Indian arm of US pharmaceutical giant Pfizer had on December 4 sought approval for its vaccine from the central drug regulator, after the firm secured such clearance in the UK and Bahrain.
Also read | DPCO-Amendment Order 2019: What Industry says
The Pune-based Serum Institute of India sought such a nod for the Oxford C-19 vaccine, Covishield, on December 6.
“DCGI has already started processing the applications. The subject expert committee on C-19 at CDSCO will deliberate on the applications by Pfizer, Serum Institute of India and Bharat Biotech seeking emergency use authorisation for their C-19 vaccines on December 9,” a source said.
At an all-party meeting on December 4, Prime Minister Narendra Modi had expressed hope that a C-19 vaccine may be ready in a few weeks.